Welcome to LookChem.com Sign In|Join Free
  • or
The chemical "3-(phenylsulfonyl)-4-(2-(4-(2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoyl)piperazin-1-yl)ethoxy)-1,2,5-oxadiazole-2-oxide" is a complex, organic compound with a molecular formula of C31H38N4O5S2. It features a 1,2,5-oxadiazole-2-oxide core, with a phenylsulfonyl group at position 3 and a substituted ethoxy group at position 4. The ethoxy group is attached to a piperazin-1-yl moiety, which is further connected to a benzoyl group. This benzoyl group is adorned with a 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio) substituent, adding to the molecule's complexity. The compound's structure is characterized by a combination of aromatic rings, aliphatic chains, and heteroatoms, making it a potentially interesting candidate for various applications in chemistry and materials science, such as pharmaceuticals or advanced materials.

1245575-23-8

Post Buying Request

1245575-23-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1245575-23-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1245575-23-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,5,5,7 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1245575-23:
(9*1)+(8*2)+(7*4)+(6*5)+(5*5)+(4*7)+(3*5)+(2*2)+(1*3)=158
158 % 10 = 8
So 1245575-23-8 is a valid CAS Registry Number.

1245575-23-8Downstream Products

1245575-23-8Relevant academic research and scientific papers

Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: Synthesis and evaluation of antihepatocellular carcinoma activity

Ling, Yong,Ye, Xiaolei,Zhang, Zhenzhen,Zhang, Yihua,Lai, Yisheng,Ji, Hui,Peng, Sixun,Tian, Jide

, p. 3251 - 3259 (2011/06/24)

Figure Presented. Novel furoxan-based nitric oxide (NO) releasing derivatives (8a-p) of farnesylthiosalicylic acid (FTS) were synthesized. Compound 8l displayed the strongest inhibition on the proliferation of human hepatocellular carcinoma (HCC) cells in vitro, superior to FTS, sorafenib, and furoxan moiety, selectively induced high frequency of HCC cell apoptosis, and produced high levels of NO in HCC cells but not in nontumor liver cells. Furthermore, 8l exhibited low acute toxicity to mice and significantly inhibited the growth of HCC tumors in vivo and the Ras-related signaling in the tumors. Therefore, our novel findings may provide a new framework for the design of new NO-releasing furoxan/FTS hybrids for the intervention of human HCC.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1245575-23-8